Details of the Drug Combination

General Information of Drug Combination (ID: DCN37EB)

Drug Combination Name
Picoplatin TEM
Indication
Disease Entry Status REF
Prostate carcinoma Investigative [1]
Component Drugs Picoplatin   DM0PIY6 TEM   DMLNFWU
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: PC-3
Zero Interaction Potency (ZIP) Score: 1.38
Bliss Independence Score: 15.52
Loewe Additivity Score: 14.62
LHighest Single Agent (HSA) Score: 14.62

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DC0898C DU-145 Investigative [1]
Adenocarcinoma DCVY6C4 HCT116 Investigative [1]
Large cell lung carcinoma DCG8LNV NCI-H460 Investigative [1]
Minimally invasive lung adenocarcinoma DCTBUB2 NCI-H322M Investigative [1]
------------------------------------------------------------------------------------

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)